✅ Suggested content. Review the technical data and compliance, adjust whatever you need and delete this line before publishing.
CJC-1295 + Ipamorelin is a research combination that brings together two peptides with complementary mechanisms on the growth hormone axis: a GHRH analog (CJC-1295) and a selective secretagogue (Ipamorelin). NeoPeptidos offers it with ≥99% HPLC purity, for research use.
Technical profile
| Product | CJC-1295 + Ipamorelin |
|---|---|
| CAS | Mezcla — ver componentes individuales |
| Molecular formula | Mezcla |
| Molecular weight | Mezcla |
| Sequence | CJC-1295 + Ipamorelin |
| Purity | 99% HPLC |
| Presentation | Lyophilized vial; bacteriostatic water included |
| Use | For scientific research use only |
What is CJC-1295 + Ipamorelin?
The logic of this combination, common in the literature, is to study two pathways at once: CJC-1295 mimics GHRH, while Ipamorelin acts on the secretagogue receptor. That is why it is described as a synergistic GHRH + secretagogue combination.
Research context
Research with this combination focuses on growth hormone release patterns when activating two complementary pathways in experimental models. For the data on each molecule, it is worth reviewing the individual profiles of CJC-1295 and Ipamorelin.
The NeoPeptidos product is research-grade material; it includes no indications or administration schedules and is intended exclusively for researchers.
Handling and reconstitution
See the reconstitution guide and the storage guide.
Quality and traceability
≥99% purity by HPLC and batch COA. See quality control.
🔬 Updated on June 8, 2026 · Reviewed by the NeoPeptidos team · Content for research purposes (RUO).